Hot off the tail of their April 1st changes, the Centers for Medicare and Medicaid Services (CMS) has already announced initial plans for the next quarterly update due at the beginning of July. Among other modifications that will be released as time goes on, this update will bring five new HCPCS Q codes that will be used for designating treatments for opioid addiction, hemophilia, cystic fibrosis, and knee pain.

The five new codes are outlined below:

 

Q9991 (Injection, buprenorphine extended release (Sublocade), less than or equal to 100 mg)

Q9992 (Injection, buprenorphine extended release (Sublocade), greater than 100 mg)

Though using buprenorphine to treat opioid addiction is nothing new, Sublocade is the latest version of the drug and was only just approved by the Food and Drug Administration (FDA) back in December. Additionally, this new drug requires that the patient have already been on a stable dose of buprenorphine for at least a full week before taking Sublocade.

 

Q9993 (Injection, triamcinolone, preservative-free, extended release, microsphere formulation, 1 mg)

This drug, used to treat skin conditions, is a less-powerful version of the popular nasal spray Nasacort. In its injected form, it can provide relief to patients with osteoarthritis in their knees.

 

Q9994 (In-line cartridge containing enzyme(s) for enteral feeding, each)

Known as Relizorb, this new drug helps break down fat. This in turn leads to more caloric absorption and better pancreatic function, which is especially useful for patients suffering from cystic fibrosis.

 

Q9995 (Injection, emicizumab-kxwh, 0.5 mg)

As a weekly injection, this drug promises to reduce the number of bleeding episodes in those diagnosed with congenital factor VIII deficiency hemophilia A with factor VIII inhibitors.

 

Though July is still months away, it will be here sooner than you think, so it never hurts to start reviewing these HCPCS Q codes and sharing them with your coworkers today.